BIODRUGS

简称 BIODRUGS ·NEW ZEALAND ·出版周期 Bimonthly ·年均收录 48 篇

6.9

最新影响因子

3.10%

自引率

较易

投稿难度

>12周，或约稿

审稿周期

期刊简介

BIODRUGS是一本专注于生物药物领域的国际学术期刊，ISSN号为1173-8804，由Springer Nature出版，出版地为新西兰，出版周期为双月刊。该期刊的影响因子根据年份有所不同，近年保持在较高水平，属于SCI收录期刊，在中科院分区中通常位于医学或药学领域的较高分区（如2区或3区）。BIODRUGS为非开放获取（OA）期刊，但部分文章可选择OA模式。其发文特点集中于生物药物研发、临床治疗应用、生物类似药、单克隆抗体、基因治疗及生物制剂的安全性评价等研究方向，尤其关注创新生物疗法的转化医学研究。杂志质量较高，审稿严格，对研究的创新性和临床意义要求较高，但需注意其拒稿率相对较高，且出版周期可能较长，投稿前需确保研究内容与期刊范围高度契合以避免风险。

影响因子趋势

近期发表

Biologic Therapies for Alleviating Neurodegeneration in Lysosomal Storage Diseases 2026-09-14

Biosimilars: A Virtuous Cycle of Sustainability and Innovation 2026-09-14

Beyond the Prevention of Anti-drug Antibody Formation with Uricase Therapy: Mechanistic Roles of DMARDs in Modifying Gout Flare Risk 2026-09-14

The Effect of Anti-drug Antibodies on the Bioavailability of Alglucosidase Alfa in Classic Infantile Pompe Disease 2026-09-11

Targeting MYC-Driven Cancers: From Oncogenic Addiction to Therapeutic Vulnerability 2026-09-02

Comparison of the Risk of Acute Anterior Uveitis Flare Between Adalimumab and Subcutaneous Infliximab in Patients with Radiographic Axial Spondyloarthritis and Prior Acute Anterior Uveitis: A Randomized Controlled Trial 2026-08-28

Targeting CD38 Across Autoimmune and Plasma Cell–Driven Immune-Mediated Diseases: Rationale, Clinical Evidence, and Emerging Therapeutic Landscape 2026-08-18

Clinical Outcomes After Week-12 Response-Guided Secukinumab Discontinuation in Psoriasis: A Prospective Real-World Cohort Study 2026-08-03

Population Pharmacokinetic Comparability of CT-P16 Versus EU-Avastin® and US-Avastin® in Healthy Subjects and Patients with Non-Squamous Non-Small Cell Lung Cancer 2026-08-02

Expanding Patient Access to Advanced Therapies 2026-07-21